Eucrisa, known under the generic name crisaborole, is intended to treat mild to moderate cases of eczema.
Pfizer gained rights to the drug through its $5.2 billion acquisition of Anacor Pharmaceuticals in the first half of 2016. The drugmaker predicts potential annual peak sales of Eucrisa to reach about $2 billion.
The drug will cost $580 for a two ounce tube and be available by the end of January, according to Pfizer.
More articles on supply chain:
Eli Lilly offers insulin discount after years of price hikes
7 supply chain lessons from auto and retail industries
FDA approves tissue repair system for knee cartilage injuries: 4 things to know
